8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 12, 2026·SEC
Material company update
Mar 9, 2026·SEC
Korro Bio, Inc.(KRRO)Earnings, Financials & Key Ratios
KRRO•NASDAQ
Price updated Jun 19, 2026
AboutKorro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.Show more
- Revenue$6M+181.5%
- EBITDA-$83M+6.0%
- Net Income-$117M-40.3%
- EPS (Diluted)-12.48-33.2%
- Gross Margin33.04%-67.0%
- EBITDA Margin-1299.47%+66.6%
- Operating Margin-1366.43%+66.2%
- Net Margin-1834.48%+50.2%
- ROE-110.7%-118.8%
KRRO Key Insights
Korro Bio, Inc. (KRRO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 34.6% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Sales declining 29.6% over 5 years
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when KRRO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KRRO Price & Volume
Korro Bio, Inc. (KRRO) stock price & volume — 10-year historical chart
Loading chart...
KRRO Growth Metrics
Korro Bio, Inc. (KRRO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-29.61%
3 Years-
TTM-20.31%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-29.84%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-23.73%
Return on Capital
10 Years-49.4%
5 Years-50.75%
3 Years-54.52%
Last Year-55.84%
KRRO Recent Earnings
Korro Bio, Inc. (KRRO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 4/12 qtrs (100%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$1.69-5.6%
$1.60
Rev
—
$761,167
Q2 2026
May 6, 2026Metric
Actual
Est
EPS
$1.69+2.1%
$1.73
Rev
—
$761,167
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$5.32-175.6%
$1.93
Rev
$1M+85.7%
$700,000
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$1.92+26.4%
$2.61
Rev
$1M+156.5%
$425,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $1.69vs $1.60-5.6% | —vs $761,167 |
| Q2 2026 | May 6, 2026 | $1.69vs $1.73+2.1% | —vs $761,167 |
| Q2 2026 | Mar 12, 2026 | $5.32vs $1.93-175.6% | $1Mvs $700,000+85.7% |
| Q4 2025 | Nov 12, 2025 | $1.92vs $2.61+26.4% | $1Mvs $425,000+156.5% |
Based on last 12 quarters of dataView full earnings history →
KRRO Peer Comparison
Korro Bio, Inc. (KRRO) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 PRME | 583.39M | 3.23 | -2.39 | 55.28% | -49.18% | -188.82% | 0.96 | |
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 ILMN | 24.6B | 161.93 | 29.71 | -0.78% | 19.43% | 32.84% | 0.94 |
Compare KRRO vs Peers
Korro Bio, Inc. (KRRO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KRRO Income Statement
Korro Bio, Inc. (KRRO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 28.95M | 36.98M | 14.07M | 0 | 0 | 2.27M | 6.39M | 3.84M |
Revenue Growth % | - | - | - | 27.76% | -61.96% | -100% | - | - | 181.46% | -20.31% |
Cost of Goods Sold | 531K | 654K | 16.81M | 1.58M | 3.84M | 0 | 0 | 0 | 4.28M | 649K |
COGS % of Revenue | - | - | 58.08% | 4.27% | 27.3% | - | - | - | 66.96% | - |
Gross Profit | -531K▲ 0% | -654K▼ 23.2% | 12.13M▲ 1955.4% | 35.4M▲ 191.8% | 10.23M▼ 71.1% | 0▼ 100.0% | 0▲ 0% | 2.27M▲ 0% | 2.11M▼ 7.0% | 3.19M▲ 0% |
Gross Margin % | - | - | 41.92% | 95.73% | 72.7% | - | - | 100% | 33.04% | 83.11% |
Gross Profit Growth % | - | -23.16% | 1955.35% | 191.78% | -71.11% | -100% | - | - | -7% | - |
Operating Expenses | 15.78M | 18.29M | 32.81M | 62.95M | 94.26M | 59M | 84.53M | 94.18M | 89.45M | 85.95M |
OpEx % of Revenue | - | - | 113.34% | 170.22% | 670.02% | - | - | 4147.12% | 1399.47% | - |
Selling, General & Admin | 3.99M | 6.71M | 14.47M | 26.3M | 34.93M | 16.8M | 36.54M | 30.55M | 28.16M | 30.49M |
SG&A % of Revenue | - | - | 50.01% | 71.11% | 248.32% | - | - | 1345% | 440.54% | - |
Research & Development | 11.79M | 11.58M | 18.33M | 36.66M | 59.32M | 42.2M | 57.25M | 63.64M | 65.58M | 58.79M |
R&D % of Revenue | - | - | 63.34% | 99.11% | 421.69% | - | - | 2802.11% | 1025.89% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -9.25M | 0 | -4.28M | -1.65M |
Operating Income | -16.31M▲ 0% | -18.94M▼ 16.2% | -20.68M▼ 9.1% | -27.55M▼ 33.3% | -84.03M▼ 205.0% | -59M▲ 29.8% | -84.53M▼ 43.3% | -91.91M▼ 8.7% | -87.34M▲ 5.0% | -82.76M▲ 0% |
Operating Margin % | - | - | -71.42% | -74.49% | -597.32% | - | - | -4047.12% | -1366.43% | -2154.03% |
Operating Income Growth % | - | -16.18% | -9.14% | -33.25% | -205.01% | 29.79% | -43.28% | -8.73% | 4.97% | - |
EBITDA | -15.78M | -18.29M | -19.86M | -25.97M | -80.19M | -56.49M | -80.9M | -88.34M | -83.06M | -79.7M |
EBITDA Margin % | - | - | -68.62% | -70.22% | -570.02% | - | - | -3890.14% | -1299.47% | -2074.52% |
EBITDA Growth % | - | -15.94% | -8.59% | -30.75% | -208.78% | 29.56% | -43.23% | -9.2% | 5.98% | 12.81% |
D&A (Non-Cash Add-back) | 531K | 654K | 813K | 1.58M | 3.84M | 2.51M | 3.63M | 3.56M | 4.28M | 3.06M |
EBIT | -20.06M | -19.06M | -18.75M | -26.48M | -83.91M | -59M | -84.53M | -91.91M | -87.34M | -61.15M |
Net Interest Income | 0 | 0 | 1.78M | 994K | -367K | 829K | 0 | 0 | 0 | 0 |
Interest Income | 0 | 0 | 1.78M | 994K | 397K | 947K | 0 | 0 | 0 | 0 |
Interest Expense | 174K | 106K | 0 | 0 | 764K | 118K | 0 | 0 | 0 | 0 |
Other Income/Expense | -3.93M | -224K | 1.93M | 1.07M | -640K | 976K | 3.39M | 8.47M | -29.28M | -30.01M |
Pretax Income | -20.24M▲ 0% | -19.17M▲ 5.3% | -18.75M▲ 2.2% | -26.48M▼ 41.2% | -84.67M▼ 219.8% | -58.02M▲ 31.5% | -81.14M▼ 39.9% | -83.44M▼ 2.8% | -116.62M▼ 39.8% | -112.77M▲ 0% |
Pretax Margin % | - | - | -64.76% | -71.59% | -601.87% | - | - | -3674.15% | -1824.51% | -2935.09% |
Income Tax | 0 | 0 | 0 | 35K | 15K | 10K | 27K | 141K | 637K | 542K |
Effective Tax Rate % | 0% | 0% | 0% | -0.13% | -0.02% | -0.02% | -0.03% | -0.17% | -0.55% | -0.48% |
Net Income | -20.24M▲ 0% | -19.17M▲ 5.3% | -18.75M▲ 2.2% | -26.51M▼ 41.4% | -84.69M▼ 219.4% | -58.03M▲ 31.5% | -81.17M▼ 39.9% | -83.58M▼ 3.0% | -117.26M▼ 40.3% | -113.5M▲ 0% |
Net Margin % | - | - | -64.76% | -71.68% | -601.98% | - | - | -3680.36% | -1834.48% | -2954.14% |
Net Income Growth % | - | 5.28% | 2.2% | -41.42% | -219.44% | 31.47% | -39.87% | -2.97% | -40.29% | -29.84% |
Net Income (Continuing) | -20.24M | -19.17M | -18.75M | -26.51M | -84.69M | -58.03M | -81.17M | -83.58M | -117.26M | -113.5M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 3.77M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -32.27▲ 0% | -30.57▲ 5.3% | -30.39▲ 0.6% | -41.10▼ 35.2% | -4.94▲ 88.0% | -227.42▼ 4503.6% | -53.08▲ 76.7% | -9.37▲ 82.3% | -12.48▼ 33.2% | -9.79▲ 0% |
EPS Growth % | - | 5.27% | 0.59% | -35.24% | 87.98% | -4503.64% | 76.66% | 82.35% | -33.19% | -23.73% |
EPS (Basic) | -32.27 | -30.57 | -30.39 | -41.10 | -4.94 | -227.58 | -53.09 | -9.37 | -12.48 | - |
Diluted Shares Outstanding | 627.09K | 627.09K | 616.89K | 645.06K | 4.45M | 255.17K | 1.53M | 8.92M | 9.4M | 11.6M |
Basic Shares Outstanding | 627.09K | 627.09K | 616.89K | 645.06K | 4.45M | 255K | 1.53M | 8.92M | 9.4M | 11.6M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
KRRO Balance Sheet
Korro Bio, Inc. (KRRO) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 17.95M | 42.94M | 221.35M | 225.06M | 134.75M | 57.08M | 172.73M | 131.53M | 82.37M | 120.16M |
Cash & Short-Term Investments | 17.94M | 42.19M | 217.35M | 220.34M | 130.71M | 55.85M | 166.15M | 126.09M | 75.16M | 113.97M |
Cash Only | 17.94M | 42.19M | 200.16M | 220.34M | 79.64M | 36.94M | 166.15M | 55.64M | 21.82M | 61.7M |
Short-Term Investments | 0 | 0 | 17.2M | 0 | 51.07M | 18.91M | 0 | 70.45M | 53.33M | 52.27M |
Accounts Receivable | 0 | 161K | 805K | 340K | 144K | 0 | 0 | 1.7M | 969K | 0 |
Days Sales Outstanding | - | - | 10.15 | 3.36 | 3.74 | - | - | 272.58 | 55.33 | 68.35 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 15K | 587K | 1M | 1.83M | 1.04M | -376K | 3.56M | 3.74M | 6.25M | 6.19M |
Total Non-Current Assets | 1.83M | 1.61M | 1.86M | 39.66M | 50.61M | 16.66M | 48.94M | 94.71M | 31.13M | 63.46M |
Property, Plant & Equipment | 1.73M | 1.51M | 1.76M | 37.84M | 36.87M | 11.89M | 42.81M | 51.55M | 16.22M | 15.62M |
Fixed Asset Turnover | - | - | 16.43x | 0.98x | 0.38x | - | - | 0.04x | 0.39x | 0.12x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 1.82M | 13.42M | 4.54M | 0 | 36.96M | 0 | 35.69M |
Other Non-Current Assets | 103K | 100K | 101K | 0 | 320K | 228K | 6.12M | 6.2M | 14.91M | 47.84M |
Total Assets | 19.79M▲ 0% | 44.55M▲ 125.1% | 223.22M▲ 401.1% | 264.72M▲ 18.6% | 185.36M▼ 30.0% | 73.74M▼ 60.2% | 221.66M▲ 200.6% | 226.24M▲ 2.1% | 113.51M▼ 49.8% | 183.62M▲ 0% |
Asset Turnover | - | - | 0.13x | 0.14x | 0.08x | - | - | 0.01x | 0.06x | 0.02x |
Asset Growth % | - | 125.14% | 401.07% | 18.59% | -29.98% | -60.22% | 200.59% | 2.06% | -49.83% | -120.4% |
Total Current Liabilities | 2.23M | 3.77M | 52.78M | 26.63M | 11.43M | 8.7M | 19.48M | 14.96M | 11.94M | 14.79M |
Accounts Payable | 994K | 1.86M | 1.22M | 5.51M | 2.75M | 2.6M | 7.28M | 3.99M | 1.65M | 1.96M |
Days Payables Outstanding | 683.26 | 1.04K | 26.46 | 1.27K | 261.14 | - | - | - | 140.8 | 1.56K |
Short-Term Debt | 0 | 0 | 0 | 397K | 2.58M | 2.92M | 0 | 0 | 2.67M | 2.8M |
Deferred Revenue (Current) | 0 | 0 | 48.15M | 14.07M | 0 | 0 | 0 | 3.51M | 7.83M | 15.27M |
Other Current Liabilities | 479K | 876K | 3.41M | 1.6M | 1.73M | 551K | 395K | 4.05M | -221K | 9.85M |
Current Ratio | 8.07x | 11.38x | 4.19x | 8.45x | 11.79x | 6.56x | 8.87x | 8.79x | 6.90x | 8.13x |
Quick Ratio | 8.07x | 11.38x | 4.19x | 8.45x | 11.79x | 6.56x | 8.87x | 8.79x | 6.90x | 8.13x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -1.49K |
Total Non-Current Liabilities | 47.2M | 85.28M | 3.08M | 45.6M | 43.1M | 164.07M | 32.27M | 50.87M | 50.13M | 49.2M |
Long-Term Debt | 46.69M | 84.94M | 0 | 15M | 14.17M | 163.86M | 0 | 0 | 0 | 40.08M |
Capital Lease Obligations | 0 | 0 | 0 | 30.6M | 28.85M | 209K | 31.22M | 43.48M | 40.81M | 124.54M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 510K | 349K | 180K | 0 | 87K | 0 | 1.05M | 1.47M | 1.48M | 9.12M |
Total Liabilities | 49.43M | 89.06M | 55.86M | 72.23M | 54.53M | 172.77M | 51.75M | 65.83M | 62.07M | 63.99M |
Total Debt | 46.69M | 84.94M | 0 | 45.99M | 45.6M | 166.99M | 33.21M | 44.77M | 43.49M | 42.88M |
Net Debt | 28.76M | 42.75M | -200.16M | -174.35M | -34.04M | 130.06M | -132.94M | -10.88M | 21.66M | -18.81M |
Debt / Equity | - | - | - | 0.24x | 0.35x | - | 0.20x | 0.28x | 0.85x | 0.36x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.54x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.24x |
Interest Coverage | -115.30x | -179.83x | - | - | -109.83x | -499.98x | - | - | - | - |
Total Equity | -29.64M▲ 0% | -44.51M▼ 50.2% | 167.36M▲ 476.0% | 192.49M▲ 15.0% | 130.82M▼ 32.0% | -99.03M▼ 175.7% | 169.91M▲ 271.6% | 160.41M▼ 5.6% | 51.44M▼ 67.9% | 119.63M▲ 0% |
Equity Growth % | - | -50.16% | 476.01% | 15.02% | -32.04% | -175.7% | 271.57% | -5.59% | -67.93% | -168.6% |
Book Value per Share | -47.27 | -70.98 | 271.29 | 298.41 | 29.42 | -388.09 | 111.10 | 17.98 | 5.47 | 10.31 |
Total Shareholders' Equity | -29.64M | -48.28M | 167.36M | 192.49M | 130.82M | -99.03M | 169.91M | 160.41M | 51.44M | 119.63M |
Common Stock | 13K | 14K | 31K | 34K | 35K | 0 | 8K | 9K | 9K | 14K |
Retained Earnings | -29.92M | -49.09M | -68.89M | -95.4M | -180.09M | -101.83M | -183M | -266.59M | -383.85M | -403.47M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 54K | 27K | -62K | -5K | 0 | 268K | 212K | 5K |
Minority Interest | 0 | 3.77M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KRRO Cash Flow Statement
Korro Bio, Inc. (KRRO) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -14.61M | -17.02M | 34.22M | -45.19M | -32.09M | -53.65M | -67.28M | -60.07M | -78.56M | -70.18M |
Operating CF Margin % | - | - | 118.2% | -122.18% | -228.13% | - | - | -2645.27% | -1229.05% | - |
Operating CF Growth % | - | -16.49% | 300.98% | -232.07% | 28.98% | -67.15% | -25.42% | 10.71% | -30.77% | -140.42% |
Net Income | -20.24M | -19.17M | -18.75M | -10.23M | -21.96M | -58.03M | -81.17M | -83.58M | -117.26M | -113.5M |
Depreciation & Amortization | 531K | 654K | 813K | 1.58M | 1.59M | 2.51M | 3.63M | 3.56M | 3.79M | 3.75M |
Stock-Based Compensation | 0 | 0 | 0 | 0 | 807K | 1.14M | 2.38M | 4.46M | 7.66M | 4.8M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | -145K | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 5.88M | 1.98M | 3.5M | -6.3M | -13.44M | 1.51M | 3.6M | 1.89M | 31.68M | 35.32M |
Working Capital Changes | 276K | 819K | 48.65M | -30.24M | 904K | -633K | 4.28M | 13.59M | -4.43M | -557K |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.7M | 727K | 1.92M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | -644K | 4.29M | 56K | 1.75M | 3.1M | -1.34M | -2.31M | -2.56M |
Cash from Investing | -1.86M | 3.34M | -18.26M | 10.4M | -39.5M | 11.06M | 11.16M | -123.35M | 43.99M | -21.03M |
Capital Expenditures | -1.86M | -436K | -1.06M | -6.67M | -4.45M | -5.21M | -7.84M | -17.9M | -518K | -420K |
CapEx % of Revenue | - | - | 3.68% | 18.04% | 31.61% | - | - | 788.29% | 8.1% | 10.93% |
Acquisitions | 0 | 3.77M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 13K | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 27.98M | 37.94M | 142.01M | 56.69M | 115.94M | 18K | 187.76M | 69.36M | 685K | 88.72M |
Debt Issued (Net) | 0 | 5M | 0 | 15M | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 27.98M | 32.94M | 142.01M | 41.69M | 115.95M | 62K | 162.71M | 67.39M | 685K | 513K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | 0 | -2K | -44K | 25.05M | 1.97M | 0 | 88.21M |
Net Change in Cash | 11.5M▲ 0% | 24.25M▲ 110.9% | 157.97M▲ 551.4% | 20.18M▼ 87.2% | 44.35M▲ 119.7% | -42.57M▼ 196.0% | 131.64M▲ 409.3% | -114.07M▼ 186.7% | -33.82M▲ 70.4% | -1.45M▲ 0% |
Free Cash Flow | -16.48M▲ 0% | -17.46M▼ 6.0% | 33.15M▲ 289.9% | -51.86M▼ 256.4% | -36.54M▲ 29.5% | -58.86M▼ 61.1% | -75.12M▼ 27.6% | -77.98M▼ 3.8% | -79.08M▼ 1.4% | -70.6M▲ 0% |
FCF Margin % | - | - | 114.52% | -140.22% | -259.75% | - | - | -3433.55% | -1237.16% | -1837.66% |
FCF Growth % | - | -5.97% | 289.87% | -256.43% | 29.54% | -61.07% | -27.63% | -3.8% | -1.41% | 5.92% |
FCF per Share | -26.28 | -27.84 | 53.74 | -80.39 | -8.22 | -230.65 | -49.12 | -8.74 | -8.42 | -6.09 |
FCF Conversion (FCF/Net Income) | 0.72x | 0.89x | -1.83x | 1.70x | 0.38x | 0.92x | 0.83x | 0.72x | 0.67x | 0.62x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 11K | 27K | 141K | 0 | 0 |
KRRO Key Ratios
Korro Bio, Inc. (KRRO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -30.52% | -14.73% | -52.39% | -365.06% | -229.04% | -50.61% | -110.7% | -117.86% |
Return on Invested Capital (ROIC) | - | - | -113.88% | -109.67% | -69.24% | -186.49% | -73.92% | -58.85% | -59.31% |
Gross Margin | - | 41.92% | 95.73% | 72.7% | - | - | 100% | 33.04% | 83.11% |
Net Margin | - | -64.76% | -71.68% | -601.98% | - | - | -3680.36% | -1834.48% | -2954.14% |
Debt / Equity | - | - | 0.24x | 0.35x | - | 0.20x | 0.28x | 0.85x | 0.36x |
Interest Coverage | -179.83x | - | - | -109.83x | -499.98x | - | - | - | - |
FCF Conversion | 0.89x | -1.83x | 1.70x | 0.38x | 0.92x | 0.83x | 0.72x | 0.67x | 0.62x |
Revenue Growth | - | - | 27.76% | -61.96% | -100% | - | - | 181.46% | -20.31% |
Related:KRRO Dividend History·KRRO Revenue History·KRRO Price History·KRRO P/E History·KRRO Financial Ratios·KRRO Institutional Holders
KRRO SEC Filings & Documents
Korro Bio, Inc. (KRRO) SEC filings — annual & quarterly reports (10-K, 10-Q)
KRRO Frequently Asked Questions
Korro Bio, Inc. (KRRO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Korro Bio, Inc. (KRRO) reported $3.8M in revenue for fiscal year 2025.
Korro Bio, Inc. (KRRO) grew revenue by 181.5% over the past year. This is strong growth.
Korro Bio, Inc. (KRRO) reported a net loss of $113.5M for fiscal year 2025.
Dividend & Returns
Korro Bio, Inc. (KRRO) has a return on equity (ROE) of -110.7%. Negative ROE indicates the company is unprofitable.
Korro Bio, Inc. (KRRO) had negative free cash flow of $70.6M in fiscal year 2025, likely due to heavy capital investments.